Drugs / azoximer bromide
azoximer bromide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04381377 | Apr 2020 → Mar 2021 | Coronaviridae infectious disease | NPO Petrovax | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03840135 | Nov 2018 → Feb 2019 | viral respiratory tract infection | NPO Petrovax | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 34
| Date | Issuer | Release |
|---|---|---|
| 2026-06-29 | NPO Petrovax | Regulatory Petrovax Pharm to launch exports of medicinal products to South Africa petrovax.com ↗
The Russian biopharmaceutical company Petrovax Pharm has obtained marketing authorization for its original medicinal product Polyoxidonium ® in the Republic of Botswana. |
| 2025-08-07 | NPO Petrovax | Regulatory Ministry of Health includes Polyoxidonium® in the federal clinical guidelines for ARVI treatment petrovax.com ↗
One of the drugs for the treatment and prevention of ARVI included in the federal guidelines this year is Polyoxidonium ® (azoximer bromide) [ 1 ] . |
| 2024-10-15 | NPO Petrovax | Results Polyoxidonium® can reduce the risk of developing acute respiratory viral infections and help recover from COVID petrovax.com ↗
A course of preventive treatment with Polyoxidonium ® (azoximer bromide) reduced the incidence of acute respiratory infections in children by almost 3 times [ 1 ] . |
| 2024-07-08 | NPO Petrovax | Results Experts evaluate role of Polyoxidonium in rhinosinusitis petrovax.com ↗
Both azoximer bromide therapy and surgery were found to improve the quality of life of patients with chronic rhinosinusitis after a 3-month period. |
| 2024-04-24 | NPO Petrovax | Results Europaediatrics Congress 2024 unveils findings concerning Polyoxidonium in managing ARVI in children petrovax.com ↗
Maksim Matsiyak, Head of Pediatrics and General Therapy Department at Petrovax, revealed the findings of a new study involving Polyoxidonium in the treatment and prevention of respiratory infections in children. |
| 2024-02-06 | NPO Petrovax | Results How to avoid getting sick during ARVI and influenza season: experts' opinion petrovax.com ↗
This study identified a statistically significant decrease in the severity of such symptoms as general weakness, muscle and joint pain, dizziness, impaired concentration and loss of sense of smell in the azoximer bromide group. |
| 2024-02-02 | NPO Petrovax | Results Russian experts attend ARVI prevention conference in Mongolia petrovax.com ↗
Mikhail Kostinov presented the results of a meta-analysis of Polyoxidonium use in the prevention of ARI and COVID infection in adults based on data from 3 clinical trials including 1141 patients aged 18 to 69 years. |
| 2023-10-30 | NPO Petrovax | Regulatory Polyoxidonium® added to updated Temporary Anti-COVID-19 Guidelines of the Russian Ministry of Health petrovax.com ↗
On October 26, 2023, the Ministry of Health approved revised temporary Anti-COVID-19 Guidelines No. 18 by adding Polyoxidonium ® thereto. |
| 2023-10-20 | NPO Petrovax | Results Doctors on child and adult sinusitis treatment methods petrovax.com ↗
We have noted a significantly faster resolution of sinusitis symptoms, such as difficult nasal breathing, headache, and nasal discharge in response to Polyoxidonium ® . |
| 2023-10-11 | NPO Petrovax | Results Children get ARVI 6 to 9 times per year while adults 2 to 4 times petrovax.com ↗
During the study, patients with high incidence of ARVI demonstrated the prophylactic efficacy of the product, i.e. the use of Polyoxidonium resulted in a significant reduction in the acute respiratory infection incidence by more than 3 times [ 4 ] . |
| 2023-03-30 | NPO Petrovax | Results Respiratory diseases are on the rise again petrovax.com ↗
The proportion of patients who received azoximer bromide and ended up with SARS-CoV-2 was only 2.44% of the total number of participants compared with more than 16% in the comparison group» |
| 2023-02-14 | NPO Petrovax | Results Russian drug helps to eliminate influenza and ARVI complications petrovax.com ↗
Aleksander Gorelov, Academician of the Russian Academy of Sciences and Infectious Diseases Specialist shared the results of a large-scale meta-analysis of the use of Polyoxidonium ® in the prevention of COVID infection in adults: |
| 2023-01-26 | NPO Petrovax | Regulatory Polyoxidonium® included in the updated Clinical Guidelines of the Russian Ministry of Health on the Influenza Prevention and Treatment in Adults petrovax.com ↗
The Ministry of Health of the Russian Federation has updated the clinical guidelines for influenza in adults [ 1 ] to include the azoximer bromide drug (Polyoxidonium ® ). |
| 2022-08-04 | NPO Petrovax | Results Study results on the use of Polyoxidonium in severe COVID Patients petrovax.com ↗
With the addition of Polyoxidonium to the treatment regimen, an increase in patient survival was noted (50% of survivors versus 35% in control group), a reduction in episodes of sepsis development (25% versus 65% in control group), the absence of septic shock and a lower need for mechanical ventilation in patients (58.3% versus 90% in control group). |
| 2022-04-08 | NPO Petrovax | Results Post-COVID syndrome: treat, not ignore petrovax.com ↗
As part of the studies among patients taking the above mentioned medicine, there was a decrease in the severity of general weakness, pain symptoms in muscles and joints, dizziness, improved concentration, and sense of smell. |
| 2021-09-14 | NPO Petrovax | Results IDTM International Journal publishes first data on the use of Polyoxidonium as preventive medicine against COVID-19 petrovax.com ↗
None of the medical professionals showed signs of disease, and their tests for COVID-19 were negative during the period of medication use. |
| 2021-07-22 | NPO Petrovax | Regulatory Russian medicine to be supplied to Slovakia under special approval for the prevention of COVID-19 petrovax.com ↗
In June this year, the Ministry of Health of the Slovak Republic approved an additional supply of original Polyoxidonium ® tablets produced by the Russian pharmaceutical company Petrovax. |
| 2021-06-08 | NPO Petrovax | Results American Society of Clinical Oncology ASCO releases the data on Polyoxidonium use in cancer therapy petrovax.com ↗
The researchers concluded that the addition of Аzoximer bromide (AB) to the standard of care for melanoma and soft tissue sarcomas is an independent favorable factor positively influencing the disease prognosis. |
| 2021-03-31 | NPO Petrovax | Results Data published in the peer-reviewed journal shows positive results in hospitalised COVID-19 patients petrovax.com ↗
NPO Petrovax Pharm, the vaccine and pharmaceutical drug development company, today announces the publication of the interim analysis of data from the Company’s trial in the Drugs in Context journal. |
| 2020-10-02 | NPO Petrovax | Results Mikhail Tsyferov speaks about international drug studies and COVID-19 vaccine manufacturing prospects in Russia at the 5th GMP conference petrovax.com ↗
The latest data provide evidence of a positive effect of Polyoxidonium ® both for COVID-19 prevention and treatment. |
| 2020-07-22 | NPO Petrovax | Results International clinical trial of Polyoxidonium® confirms its safety for COVID-19 treatment petrovax.com ↗
Results of an international clinical trial launched this April, confirmed that Polyoxidonium ® (INN: Azoximer bromide, manufactured by Petrovax) had a high safety profile for COVID-19 treatment. |
| 2020-04-23 | NPO Petrovax | Regulatory Russian Petrovax ramps up pharmaceutical production driven by COVID-19 pandemic petrovax.com ↗
In April, Petrovax was issued a MoH’s approval for international multicenter clinical trials to study Polyoxidonium ® efficacy and safety in hospitalized COVID-19 patients. |
| 2020-04-17 | NPO Petrovax | Regulatory Polyoxidonium (INN: Azoximer bromide) has been included into Temporary Guidelines for ARVI during COVID-19 pandemic petrovax.com ↗
Polyoxidonium (INN: Azoximer bromide) has been included into Temporary Guidelines for ARVI during COVID-19 pandemic |
| 2019-11-08 | NPO Petrovax | Results An Additional Component Can Triple Vaccine Efficiency, and Scientists Explained How petrovax.com ↗
A team of Russian scientists carried out a study on the cell immunity level and found out how an adjuvant called azoximer bromide increases the immunogenicity of the anti-flu vaccine. |
| 2019-04-11 | NPO Petrovax | Results In Europe, the results of the latest study on the adjuvant role as an influenza vaccine ingredient were presented petrovax.com ↗
At the Edinburgh conference, the Russian experts shared with their colleagues the history of multi-year research efforts and presented the results of Polyoxidonium use as a component of the novel vaccine Grippol ® Quadrivalent. |
| 2017-11-21 | NPO Petrovax | Results EU PASS findings on Russian originator product Polyoxidonium® reported at an international conference petrovax.com ↗
In 2017, the company received a positive study report that provided evidence of the product’s high safety profile and acceptable tolerability by patients. |
| 2017-08-03 | NPO Petrovax | Regulatory Polyoxidonium® approved for new applications, now in children aged 3+ years petrovax.com ↗
The PIL change was approved by the Russian Ministry of Health. |
| 2017-07-31 | NPO Petrovax | Results Polyoxidonium Post Authorization Safety Study (PASS) data in Europe confirmed its high safety profile petrovax.com ↗
The study confirmed the product’s high safety profile and favorable tolerability among patients. |
| 2017-07-03 | NPO Petrovax | Regulatory Polyoxidonium® scope extended to include children aged 3+ years petrovax.com ↗
The PIL change was approved by the Russian Ministry of Health on 01.06.2017. |
| 2016-11-01 | NPO Petrovax | Regulatory NPO Petrovax Pharm pioneers Russian GMP certificate to manufacture veterinary medicines petrovax.com ↗
In October 2016, the Federal Service for Veterinary and Phytosanitary Surveillance (Rosselkhoznadzor), following the audit, approved the issue of a GMP certificate for NPO Petrovax Pharm to manufacture the veterinary medicines AZOXIVET and Vetolaza. |
| 2013-02-20 | NPO Petrovax | Results Russia’s Leading Professionals Discuss Paediatrics and Vaccination at 17th Summit of Paediatricians of Russia petrovax.com ↗
Treating them with Polyoxidonium® for 12 days (IM, 0.15 mg/kg) helped to reliably reduce the frequency rate of intercurrent infections in 72% of bronchial asthma patients, improved external respiration and immune response parameters, and reduced the persistence of infectious agents. |
| 2011-02-02 | NPO Petrovax | Regulatory Polyoxidonium® — now for veterinary use petrovax.com ↗ |
| 2010-04-01 | NPO Petrovax | Regulatory Petrovax Group registers Polyoxidonium® price petrovax.com ↗ |
| 2009-10-19 | NPO Petrovax | Regulatory Petrovax Group was issued MA’s for two influenza A/H1N1 vaccines petrovax.com ↗
On October 16th, Petrovax Group, a Russian innovative vaccine and pharmaceutical developer and manufacturer, was issued marketing authorizations for MonoGrippol Neo and MonoGrippol vaccines. |
All press releases naming this drug 48 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | azoximer bromide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04381377 ↗ |
| Known as | Polyoxidonium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03840135 ↗ |
| Known as | Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml | “Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml” NCT03840135 ↗ |
| Modality | Small molecule | — CHEMBL4650378 ↗ |
| Route | Intranasal | “1 spray intranasally (in each nasal passage)” NCT03840135 ↗ |